{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:39:29Z","timestamp":1789695569130,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG024904"],"award-info":[{"award-number":["U01 AG024904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-2-0012"],"award-info":[{"award-number":["W81XWH-12-2-0012"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014041","name":"Alzheimer's Disease Neuroimaging Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020275","name":"TauRx Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tjpad.2026.100560","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:30:50Z","timestamp":1776468650000},"page":"100560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer\u2019s disease with hydromethylthionine mesylate using external control data"],"prefix":"10.1016","volume":"13","author":[{"given":"Bjoern O","family":"Schelter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Shiells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3378-7028","authenticated-orcid":false,"given":"Serena","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9396-0443","authenticated-orcid":false,"given":"Nafeesa","family":"Nazlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9570-9416","authenticated-orcid":false,"given":"Emily","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bentham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-3021","authenticated-orcid":false,"given":"Gordon K","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-0813","authenticated-orcid":false,"given":"Lutz","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"MacSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Tai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tay Siew","family":"Choon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahe","family":"Asvatourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Muehlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Priel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenecia","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Downie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Pringle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M\u2024D","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Baddeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-8673","authenticated-orcid":false,"given":"Roger","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5555-4129","authenticated-orcid":false,"given":"Anca-Larisa","family":"Sandu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-6279","authenticated-orcid":false,"given":"Claire","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stefanacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude M","family":"Wischik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100560_bib0001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.tjpad.2026.100560_bib0002","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.jmb.2018.08.010","article-title":"Cysteine-independent inhibition of Alzheimer\u2019s disease-like paired helical filament assembly by leuco-methylthioninium (LMT)","volume":"430","author":"Al-Hilaly","year":"2018","journal-title":"J Mol Biol"},{"key":"10.1016\/j.tjpad.2026.100560_bib0003","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1074\/jbc.M114.616029","article-title":"Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease","volume":"290","author":"Harrington","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tjpad.2026.100560_bib0004","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jnc.15553","article-title":"Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine","volume":"160","author":"Kondak","year":"2022","journal-title":"J Neurochem"},{"key":"10.1016\/j.tjpad.2026.100560_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310810","article-title":"Mitochondrial effects of hydromethylthionine, rivastigmine and memantine in tau-transgenic mice","volume":"24","author":"Kondak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjpad.2026.100560_bib0006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-008-1394-2","article-title":"Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine","volume":"202","author":"Deiana","year":"2009","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.tjpad.2026.100560_bib0007","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FBP.0000000000000865","article-title":"Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer\u2019s disease","volume":"37","author":"Robinson","year":"2026","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.tjpad.2026.100560_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2026.100480","article-title":"Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer\u2019s disease","volume":"13","author":"Wischik","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100560_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70539","article-title":"Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer\u2019s disease explains unexpected Phase 3 trial results","author":"van Maanen","year":"2026","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.tjpad.2026.100560_bib0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.tjpad.2026.100560_bib0011","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14283\/jpad.2022.63","article-title":"Oral tau aggregation inhibitor for Alzheimer\u2019s disease: design, progress and basis for selection of the 16 mg\/day dose in a phase 3, randomized, placebo-controlled trial of hydromethylthionine mesylate","volume":"9","author":"Wischik","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100560_bib0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.tjpad.2026.100560_bib0013","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.tjpad.2026.100560_bib0015","unstructured":"C-Path. Critical path for Alzheimer\u2019s disease. Available from: https:\/\/C-PathOrg\/Program\/Critical-Path-for-Alzheimers-Disease\/2008."},{"key":"10.1016\/j.tjpad.2026.100560_bib0016","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"2018"},{"key":"10.1016\/j.tjpad.2026.100560_bib0017","unstructured":"Greifer N. WeightIt: weighting for covariate balance in observational studies. R package version 1.5.1. 2025. n.d."},{"key":"10.1016\/j.tjpad.2026.100560_bib0018","series-title":"Draft guideline on the use of external control arms based on realworld data to support regulatory decisions","year":"2025"},{"key":"10.1016\/j.tjpad.2026.100560_bib0019","series-title":"FDA converts novel Alzheimer\u2019s disease treatment to traditional approval","year":"2023"},{"key":"10.1016\/j.tjpad.2026.100560_bib0020","series-title":"Choice of control group and related issues in clinical trials E10 2000","year":"2025"},{"key":"10.1016\/j.tjpad.2026.100560_bib0021","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13195-020-00630-5","article-title":"Testing whether the progression of Alzheimer\u2019s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data","volume":"12","author":"Zhang","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100560_bib0022","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory Phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.tjpad.2026.100560_bib0023","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer\u2019s disease: rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.tjpad.2026.100560_bib0024","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer\u2019s disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J Prev Alzheimers Dis"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:40:52Z","timestamp":1780339252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2274580726000841"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100560","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer\u2019s disease with hydromethylthionine mesylate using external control data","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100560"}}